Skip to main content
Premium Trial:

Request an Annual Quote

Valentis Receives New Warning from Nasdaq

NEW YORK, April 7 - Valentis said that it received a Nasdaq staff determination letter on March 28 for not maintaining a sufficient number of independent members of its board of directors and for violating a shareholder approval requirement.

 

Nasdaq warned that the company did not comply with audit committee composition requirements, as described in rules 4350(c) and 4350(d)(2), which call for an audit committee of at least three independent members, at least one of whom has had past employment experience in finance or accounting.

 

The letter also stated that Valentis granted a stock option that did not comply with the shareholder approval requirement set forth in rule 4350(i)(1)(A), which requires shareholder approval when stock is acquired by officers or directors.

 

Valentis said that is has submitted a written response to Nasdaq stating its reasons for believing it is in compliance with the above-mentioned rules.

 

In August, Valentis received a warning that its market capitalization failed to comply with Nasdaq's $50 million minimum. The company avoided delisting in November with a restructuring plan that included a reverse stock split and a conversion of its Series A preferred stock to common stock.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.